US20150024062A1 - Medical Food for the Dietary Management of Major Depression - Google Patents

Medical Food for the Dietary Management of Major Depression Download PDF

Info

Publication number
US20150024062A1
US20150024062A1 US14/282,322 US201414282322A US2015024062A1 US 20150024062 A1 US20150024062 A1 US 20150024062A1 US 201414282322 A US201414282322 A US 201414282322A US 2015024062 A1 US2015024062 A1 US 2015024062A1
Authority
US
United States
Prior art keywords
hod
water
mol
medical food
isotopologue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/282,322
Inventor
Igor Anatolyevich Pomytkin
Anton Sergeevich Chernopyatko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US14/282,322 priority Critical patent/US20150024062A1/en
Publication of US20150024062A1 publication Critical patent/US20150024062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A23L1/30—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention is in the field of food industry and healthcare. More specifically, the present invention relates to medical foods for the dietary management of major depression.
  • Major depression is a disorder characterized by a combination of symptoms such as lowered mood, loss of energy, loss of interest, feeling of physical illness, poor concentration, altered appetite, altered sleep and a slowing down of physical and mental functions resulting in a relentless feeling of hopelessness, helplessness, and guilt.
  • MDD major depressive disorder
  • National Institute of Mental Health estimates prevalence of major depressive disorder (MDD) as 6.7% of U.S. adult population, 56.8% of those with disorders are receiving treatment.
  • MDD is a major cause of disability and premature death. Average-age-of onset of MDD is estimated as of 32 years old. The exact cause of MDD is not known.
  • Present treatment of depression consists of psychotherapy, antidepressant drugs, or a combination of both. However, there are no special nutritional requirements related to the dietary management of patients with MDD.
  • Water is an essential nutrient. Total water intake includes drinking water, water in beverages, and water contained in food. The adequate intake for total water was set based on the median total water intake from U.S. survey data as 3.7 and 2.7 liters per day for men and women, respectively. Dietary Guidelines for Americans, 2005, U.S. Department of Health & Human Services.
  • the natural water is a composition of nine water isotopologues (H 2 16 O, H 2 17 O, H 2 18 O, H 16 OD, H 17 OD, H 18 OD, D 2 16 O, D 2 17 O, D 18 O) formed by stable isotopes of hydrogen (H and D) and oxygen ( 16 O, 17 O, 18 O), wherein content of major water isotopologue H 2 O (H 2 16 O) is 99.7317 molecular % (mol. %) and major deuterium-containing isotopologue HOD (H 16 OD) is 0.0311 mol. % (Vienna Standard Mean Ocean Water, VSMOW). Rothman et al., J. Quant. Spectrosc. Radiat.
  • HOD levels in natural water slightly vary on Earth district. Only exclusion is natural water of Antarctica, which water contains HOD at levels of about 0.0178 mol. % (Standard Light Antarctic Precipitation, SLAP). A majority of people reside at Earth districts, where they consume natural water with HOD levels from 0.0280 to 0.0311 mol. %. On a calculation basis, when consume 2.7 and 3.7 liters of natural water per day, women and men consume no less than 0.8 and 1.0 ml of HOD as the obligate nutrient per day, respectively.
  • HOD is a highly undesirable nutrient for a subject suffering from depression and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone.
  • mammals are highly sensitive to HOD levels in drinking water and even change of HOD content in drinking water within the range of its natural concentrations provides a significant effect on susceptibility to psychosocial stress and predisposition to the development of depression.
  • the dietary management of major depression can be achieved by restriction of HOD daily consumption.
  • It is an object of the present invention is to provide a medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 molecular % of isotopologue HOD.
  • the present invention provides a medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 molecular % of isotopologue HOD.
  • the medical food comprises water containing from 0.0178 to 0.0278 molecular % of isotopologue HOD.
  • medical food refers to a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of depression and/or anxiety, for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.
  • the medical food is specially formulated and processed as a drink product.
  • drink products include, but are not limited by, drinking water, beverage, and liquid food.
  • major depression also known as major depressive disorder
  • major depressive disorder refers to a mental disorder typically characterized by a lasting sad mood and/or loss of interest or pleasure in most activities.
  • isotopologue is in accordance with IUPAC Compendium of Chemical Terminology 2nd Edition (1997) and refers to a molecular entity that differs only in isotopic composition (number of isotopic substitutions).
  • examples of such isotopologues include H 2 16 O, H 2 17 O, H 2 18 O, H 16 OD, H 17 OD, 1 H 18 OD, D 2 16 O, D 2 17 O, and D 2 18 O.
  • the isotopologue H 16 OD is indicated in the present invention as HOD.
  • HOD content in the water can be determined by methods well-known from the art.
  • HOD levels can be directly measured by laser spectrometry.
  • HOD levels can be determined by conventional isotope mass-spectrometry as D/H ratio and re-calculated to HOD contents given that content of other deuterium-containing isotopologues in water is negligible as compared to HOD.
  • VSMOW water contains 0.00006 mol. % H 18 OD; 0.00001 mol.
  • the range 0.0002 to 0.0278 mol. % of isotopologue HOD in the water of the invention corresponds to the range of D/H ratio 1 to 139 ppm.
  • the range 0.0178 to 0.0278 mol. % of isotopologue HOD in the water of the invention corresponds to the range of deuterium content 89 to 139 ppm.
  • the water containing 0.0002 to 0.0278 mol. % of isotopologue HOD can be prepared by a variety of industrial procedures well-known from the art, e.g. vacuum distillation of natural water.
  • the water containing 0.0178 to 0.0278 mol. % of isotopologue HOD can be obtained from rare natural sources (e.g. Antarctic precipitations) or prepared by a variety of industrial procedures well-known from the art, e.g. vacuum distillation of natural water.
  • the medical food of the invention may be prepared by well-known procedures using well-known optional ingredients.
  • Such optional ingredients generally are used individually at levels from about 0.0005% to about 10.0%, preferably from about 0.005% to about 1.0% by weight of the composition.
  • suitable optional ingredients include, but are not limited to, buffers, sweeteners, colorants, carriers, and etc.
  • the medical food is a liquid medical food specially formulated and manufactured in form of drinking water or beverage.
  • the liquid medical food may be prepared by saturation of water containing 0.0002 to 0.0278 mol. % of isotopologue HOD with carbon dioxide or/and inorganic salts typically abandoned in natural drinking water.
  • the examples of such salts include, but are not limited to, sodium chloride, sodium bicarbonate, calcium chloride, magnesium sulfate, etc.
  • the medical food can be administered orally for a period of one day or longer and in amounts as prescribed by a physician which manages the diet and/or provides medical supervision.
  • the medical food may be formulated as the drinking water or beverage that can be administered in amounts from 0.1 to 4.0 liters per subject per day.
  • the medical food may be consumed by mammals.
  • mammals include, but are not limited to, animals such as a dog, a cat, a horse, and a human.
  • the medical food is consumed by a human.
  • This example demonstrates the preparation of water samples with different contents of isotopologue HOD.
  • the samples were prepared by mixing in certain proportions the conventional distilled water containing 0.0300 mol. % HOD and water containing 0.0002 mol. % HOD, wherein the last water was prepared by high-effective vacuum distillation of the conventional distilled water at 60° C. and pressure 0.2 bars using the distillation column of 10 m of height.
  • HOD levels were measured by isotope laser spectroscopy using Los Gatos Research (LGR) Liquid Water Isotope Analyzer.
  • Table 1 shows water samples comprising 0.0002 to 0.0278 mol. % of isotopologue HOD and D/H ratios corresponding therewith.
  • This example demonstrates the medical food for the dietary management of major depression.
  • the medical foods were formulated as mineralized drinking waters with HOD content as indicated in Table 2.
  • the medical foods No 1 through 4 were prepared by dissolution of Calcium Chloride, Magnesium Chloride, and Sodium Bicarbonate in Waters No 1 through 4, respectively, and subsequent bottling in bottles of 330 ml volume.
  • Results of forced swim test are presented in Table 4 as mean ⁇ SEM latency to floating (Latency) and duration of floating (Duration). As shown in Table 4, the increase in HOD levels in drinking water results in significant decrease in the latency to floating and increase in the duration of floating, meaning that deuterium-containing isotopologue HOD predisposes to the development of depression.
  • HOD is a very undesirable nutrient for elderly subjects with depressive disorders and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 mol. % of isotopologue HOD, preferably, from 0.0178 to 0.0278 mol. % of isotopologue HOD.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a divisional of application Ser. No. 13/686,372 filed Nov. 27, 2012, which is incorporated herein by reference, and which claims priority on Russian patent application 2011149370 filed Dec. 5, 2011, which priority claim is repeated here.
    • FIELD OF THE INVENTION
  • The present invention is in the field of food industry and healthcare. More specifically, the present invention relates to medical foods for the dietary management of major depression.
    • BACKGROUND OF THE INVENTION
  • Major depression is a disorder characterized by a combination of symptoms such as lowered mood, loss of energy, loss of interest, feeling of physical illness, poor concentration, altered appetite, altered sleep and a slowing down of physical and mental functions resulting in a relentless feeling of hopelessness, helplessness, and guilt. National Institute of Mental Health estimates prevalence of major depressive disorder (MDD) as 6.7% of U.S. adult population, 56.8% of those with disorders are receiving treatment. Worldwide, MDD is a major cause of disability and premature death. Average-age-of onset of MDD is estimated as of 32 years old. The exact cause of MDD is not known. Present treatment of depression consists of psychotherapy, antidepressant drugs, or a combination of both. However, there are no special nutritional requirements related to the dietary management of patients with MDD.
  • Water is an essential nutrient. Total water intake includes drinking water, water in beverages, and water contained in food. The adequate intake for total water was set based on the median total water intake from U.S. survey data as 3.7 and 2.7 liters per day for men and women, respectively. Dietary Guidelines for Americans, 2005, U.S. Department of Health & Human Services. The natural water is a composition of nine water isotopologues (H2 16O, H2 17O, H2 18O, H16OD, H17OD, H18OD, D2 16O, D2 17O, D18O) formed by stable isotopes of hydrogen (H and D) and oxygen (16O, 17O, 18O), wherein content of major water isotopologue H2O (H2 16O) is 99.7317 molecular % (mol. %) and major deuterium-containing isotopologue HOD (H16OD) is 0.0311 mol. % (Vienna Standard Mean Ocean Water, VSMOW). Rothman et al., J. Quant. Spectrosc. Radiat. Transfer, 1998, 60, 665. Rothman et al., J. Quant. Spectrosc. Radiat. Transfer, 2003, 82, p.9. Because of process of evaporation and condensation of ocean water, HOD levels in natural water slightly vary on Earth district. Only exclusion is natural water of Antarctica, which water contains HOD at levels of about 0.0178 mol. % (Standard Light Antarctic Precipitation, SLAP). A majority of people reside at Earth districts, where they consume natural water with HOD levels from 0.0280 to 0.0311 mol. %. On a calculation basis, when consume 2.7 and 3.7 liters of natural water per day, women and men consume no less than 0.8 and 1.0 ml of HOD as the obligate nutrient per day, respectively.
  • We discovered that HOD is a highly undesirable nutrient for a subject suffering from depression and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone. Surprisingly, we found that mammals are highly sensitive to HOD levels in drinking water and even change of HOD content in drinking water within the range of its natural concentrations provides a significant effect on susceptibility to psychosocial stress and predisposition to the development of depression. Thus, the dietary management of major depression can be achieved by restriction of HOD daily consumption.
  • It is an object of the present invention is to provide a medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 molecular % of isotopologue HOD.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 molecular % of isotopologue HOD.
  • In a preferred embodiment of the invention, the medical food comprises water containing from 0.0178 to 0.0278 molecular % of isotopologue HOD.
  • As used herein, the term “medical food” refers to a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of depression and/or anxiety, for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.
  • In a preferred embodiment of the invention, the medical food is specially formulated and processed as a drink product. Such drink products include, but are not limited by, drinking water, beverage, and liquid food.
  • As used herein, the term “major depression” (also known as major depressive disorder) refers to a mental disorder typically characterized by a lasting sad mood and/or loss of interest or pleasure in most activities.
  • As used herein, the term “isotopologue” is in accordance with IUPAC Compendium of Chemical Terminology 2nd Edition (1997) and refers to a molecular entity that differs only in isotopic composition (number of isotopic substitutions). Examples of such isotopologues include H2 16O, H2 17O, H2 18O, H16OD, H17OD, 1H18OD, D2 16O, D2 17O, and D2 18O. The isotopologue H16OD is indicated in the present invention as HOD.
  • In preferred embodiments of the invention, HOD content in the water can be determined by methods well-known from the art. HOD levels can be directly measured by laser spectrometry. R. Van Trigt. R. van Trigt. Laser Spectrometry for Stable Isotope Analysis of Water Biomedical and Paleoclimatological Applications. 2002, Groningen: University Library Groningen. Also, HOD levels can be determined by conventional isotope mass-spectrometry as D/H ratio and re-calculated to HOD contents given that content of other deuterium-containing isotopologues in water is negligible as compared to HOD. For the reference, VSMOW water contains 0.00006 mol. % H18OD; 0.00001 mol. % H17OD; and less than 0.00001 mol. % for sum of isotopologues D2 16O, D2 17O, and D2 18O. The range 0.0002 to 0.0278 mol. % of isotopologue HOD in the water of the invention corresponds to the range of D/H ratio 1 to 139 ppm. The range 0.0178 to 0.0278 mol. % of isotopologue HOD in the water of the invention corresponds to the range of deuterium content 89 to 139 ppm.
  • In preferred embodiments of the invention, the water containing 0.0002 to 0.0278 mol. % of isotopologue HOD can be prepared by a variety of industrial procedures well-known from the art, e.g. vacuum distillation of natural water. The water containing 0.0178 to 0.0278 mol. % of isotopologue HOD can be obtained from rare natural sources (e.g. Antarctic precipitations) or prepared by a variety of industrial procedures well-known from the art, e.g. vacuum distillation of natural water.
  • In practicing the invention, the water containing 0.0002 to 0.0278 mol. % of isotopologue HOD may contain other water isotopologues at levels equal or other than in VSMOW standard of natural water, e.g. 0<H2 18O≦0.2000 mol. %; 0<H2 17O≦0.0370 mol. %; 0<H17OD≦0.0270 mol. %; 0<H18OD≦0.0270 mol. %; 0<D2 16O≦0.0270 mol. %; 0<D2 17O≦0.0270 mol. %; 0<D2 18O=0.0270 mol. %, and 0<H2 16≦99.9998 mol. %.
  • The medical food of the invention may be prepared by well-known procedures using well-known optional ingredients. Such optional ingredients generally are used individually at levels from about 0.0005% to about 10.0%, preferably from about 0.005% to about 1.0% by weight of the composition. Examples of suitable optional ingredients include, but are not limited to, buffers, sweeteners, colorants, carriers, and etc.
  • In the preferred embodiments of the invention, the medical food is a liquid medical food specially formulated and manufactured in form of drinking water or beverage. The liquid medical food may be prepared by saturation of water containing 0.0002 to 0.0278 mol. % of isotopologue HOD with carbon dioxide or/and inorganic salts typically abandoned in natural drinking water. The examples of such salts include, but are not limited to, sodium chloride, sodium bicarbonate, calcium chloride, magnesium sulfate, etc.
  • In practicing the invention, the medical food can be administered orally for a period of one day or longer and in amounts as prescribed by a physician which manages the diet and/or provides medical supervision.
  • In practicing the invention, the medical food may be formulated as the drinking water or beverage that can be administered in amounts from 0.1 to 4.0 liters per subject per day.
  • In practicing the invention, the medical food may be consumed by mammals. Nonexclusive examples of such mammals include, but are not limited to, animals such as a dog, a cat, a horse, and a human. Preferably, the medical food is consumed by a human.
  • The following examples are presented to demonstrate the invention. The examples are illustrative only and are not intended to limit the scope of the invention in any way.
    • EXAMPLE 1
  • This example demonstrates the preparation of water samples with different contents of isotopologue HOD. The samples were prepared by mixing in certain proportions the conventional distilled water containing 0.0300 mol. % HOD and water containing 0.0002 mol. % HOD, wherein the last water was prepared by high-effective vacuum distillation of the conventional distilled water at 60° C. and pressure 0.2 bars using the distillation column of 10 m of height. HOD levels were measured by isotope laser spectroscopy using Los Gatos Research (LGR) Liquid Water Isotope Analyzer. Table 1 shows water samples comprising 0.0002 to 0.0278 mol. % of isotopologue HOD and D/H ratios corresponding therewith.
  • TABLE 1
    Water samples
    Sample HOD content, mol. % D/H ratio, ppm
    Water No 1 0.0278 139
    Water No 2 0.0240 120
    Water No 3 0.0178 89
    Water No 4 0.0002 1
    • EXAMPLE 2
  • This example demonstrates the medical food for the dietary management of major depression. The medical foods were formulated as mineralized drinking waters with HOD content as indicated in Table 2.
  • TABLE 2
    Medical foods
    Ingredient (HOD, mol. %) Content, wt. %
    Medical food 1
    Water No 1 (0.0278) 99.953
    Calcium Chloride 0.015
    Magnesium Chloride 0.007
    Sodium Bicarbonate 0.025
    Medical food 2
    Water No 2 (0.0240) 99.953
    Calcium Chloride 0.015
    Magnesium Chloride 0.007
    Sodium Bicarbonate 0.025
    Medical food 3
    Water No 3 (0.0178) 99.953
    Calcium Chloride 0.015
    Magnesium Chloride 0.007
    Sodium Bicarbonate 0.025
    Medical food 4
    Water No 4 (0.0002) 99.953
    Calcium Chloride 0.015
    Magnesium Chloride 0.007
    Sodium Bicarbonate 0.025
  • The medical foods No 1 through 4 were prepared by dissolution of Calcium Chloride, Magnesium Chloride, and Sodium Bicarbonate in Waters No 1 through 4, respectively, and subsequent bottling in bottles of 330 ml volume.
    • EXAMPLE 3
  • This example shows that deuterium-containing isotopologue HOD dose-dependently predisposes to the development of depression. Water samples of Table 3 were prepared by mixing in certain proportions of two equally mineralized waters having HOD level of 0.0184 mol. % (D/H ratio=92 ppm) and HOD level 0.0282 mol. % (D/H ratio=141 ppm).
  • TABLE 3
    Water samples
    Water sample HOD content, mol. % D/H ratio, ppm
    W1 0.0184 92
    W2 0.0240 120
    W3 0.0258 129
    W4 0.0282 141

    Three-months-old male C57BI/6 mice were randomly assigned by 15 animals per group and received W1, W2, W3, and W4 (Table 3) as drinking waters ad libitum for 14 days and then were tested for depressive-like behavior in a forced swim test and novel cage test, commonly accepted paradigms for pre-clinical testing of a depressive-like behavior. Antidepressant Imipramine (15 mg/kg per day) was administered to mice that were taken as positive control in the test. Results of forced swim test are presented in Table 4 as mean±SEM latency to floating (Latency) and duration of floating (Duration). As shown in Table 4, the increase in HOD levels in drinking water results in significant decrease in the latency to floating and increase in the duration of floating, meaning that deuterium-containing isotopologue HOD predisposes to the development of depression.
  • TABLE 4
    Forced swim test
    Sample (HOD, mol. %) Latency, s Duration, s
    W1 (0.0184) 46 ± 6#  89 ± 15#
    W2 (0.0240) 48 ± 9#  80 ± 14#
    W3 (0.0258) 47 ± 11# 86 ± 19#
    W4 (0.0282) 31 ± 6*  128 ± 12* 
    Imipramine 58 ± 4*# 79 ± 8#*
    *Differs significantly of W1 (p < 0.05).
    #Differs significantly of W4 (p < 0.05).

    Results of novel cage test are presented in Table 5 as mean±SEM number of exploratory rearings in the new cage. As found, the increase in HOD levels in drinking water results in significant decrease in the number of exploratory rearings in the new cage, meaning that deuterium-containing isotopologue HOD predisposes to the development of depression.
  • TABLE 5
    Novel cage test
    Sample (HOD, mol. %) Number, n
    W1 (0.0184) 35.0 ± 1.5#
    W2 (0.0240) 35.5 ± 1.5#
    W3 (0.0258) 33.0 ± 1.5 
    W4 (0.0282)  30.0 ± 1.0*
    Imipramine 34.0 ± 1.5#
    *Differs significantly of W1 (p < 0.05).
    #Differs significantly of W4 (p < 0.05).

    Thus, these results suggest that deuterium-containing water isotopologue HOD in drinking water predisposes to depressive-like behavior. Therefore, HOD is a very undesirable nutrient for subjects with major depressive disorder and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone.
    • EXAMPLE 4
  • This example demonstrates that deuterium-containing isotopologue HOD predisposes to the development of anhedonia, the core symptom of depression. Young adult male C57BI/6J mice received ad libitum waters W1 or W4 (Table 3) for one week prior the onset of stress and during the ten days of a chronic stress. Citalopram 15 mg/kg per day per os was used as the reference antidepressant drug. There was no difference between groups at baseline. At 10th day of the stress procedure, animals were tested on the sucrose preference, common test for assessment of anhedonia. Results are presented in Table 6 as mean±SEM percent of sucrose preference.
  • TABLE 6
    Sucrose preference test
    Group (HOD, mol. %) Sucrose preference, %
    W1 (0.0184) 73.5 ± 3.0#
    W4 (0.0282)  62.5 ± 2.0*
    Citalopram 70.0 ± 3.0#
    *Differs significantly of W1 (p < 0.05).
    #Differs significantly of W4 (p < 0.05).

    As shown in Table 6, the increase in HOD levels in drinking water results in significant decrease in sucrose preference, meaning that deuterium-containing isotopologue HOD predisposes to the development of anhedonia, the core symptom of depression. Therefore, HOD is a very undesirable nutrient for subjects with major depressive disorder and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone.
    • EXAMPLE 5
  • This example demonstrates that deuterium-containing isotopologue HOD predisposes to the development of depression in elderly. Table 7 shows that sucrose preference in old C5BI/6J mice is significantly decreased in comparison with young adult C5BI/6J mice, meaning that normal aging induces spontaneous anhedonia in mice.
  • TABLE 7
    Group Sucrose preference, %
    Young adult C57BI/6J mice (3 months old) 78.0 ± 2.5 
    Old C57BI/6J mice (18 months old) 60.6 ± 3.1*
    *Differs significantly of young adult mice (p < 0.05).

    To estimate effect of HOD on anhedonia in elderly, 18 month old male C57BI/6J mice received ad libitum waters W1 or W4 (Table 3) for 14 days. There was no difference between groups at baseline. At the end of the experiment, mice were tested in sucrose preference test. Results are presented in Table 8 as mean±SEM percent of sucrose preference. As found, the increase in HOD levels in drinking water results in significant decrease in sucrose preference, meaning that deuterium-containing isotopologue HOD predisposes to the development of anhedonia, the core symptom of major depression, in elderly.
  • TABLE 8
    Sucrose preference test
    Group (HOD, mol. %) Sucrose preference, %
    W1 (0.0184) 81.3 ± 1.9 
    W4 (0.0282) 69.4 ± 4.4*
    *Differs significantly of W1 (p < 0.05).

    To estimate effect of HOD on depressive-like behavior in elderly, 18 month old male C57BI/6J mice received ad libitum waters W1 or W4 (Table 3) for 14 days. There was no difference between groups at baseline. At the end of the experiment, mice were tested in forced swim test. Results are presented in Table 9 as mean±SEM of latency to floating (Latency) and duration of floating (Duration). As found, the increase in HOD levels in drinking water results in decrease in the latency to floating and significant increase in the duration of floating, meaning that deuterium-containing isotopologue HOD predisposes to the development of depression in elderly.
  • TABLE 9
    Forced swim test
    Group (HOD, mol. %) Latency, s Duration, s
    W1 (0.0184) 17.4 ± 4.2 126.7 ± 13.9 
    W4 (0.0282) 13.7 ± 3.1 186.7 ± 10.0*
    *Differs significantly of W1 (p < 0.05).
  • Therefore, HOD is a very undesirable nutrient for elderly subjects with depressive disorders and HOD restriction may represent a special medically determined nutrient requirement, the dietary management of which cannot be achieved by the modification of the normal diet alone.

Claims (2)

We claim:
1. A medical food for the dietary management of major depression comprising a water containing from 0.0002 to 0.0278 molecular % of isotopologue HOD.
2. The medical food of claim 1, wherein the water contains from 0.0178 to 0.0278 molecular % of isotopologue HOD.
US14/282,322 2011-12-05 2014-05-20 Medical Food for the Dietary Management of Major Depression Abandoned US20150024062A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/282,322 US20150024062A1 (en) 2011-12-05 2014-05-20 Medical Food for the Dietary Management of Major Depression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2011149370 2011-12-05
RU2011149370/13A RU2482706C1 (en) 2011-12-05 2011-12-05 Therapeutic nutrition for dietary control of depression and anxious disorders and its application method
US13/686,372 US9220727B2 (en) 2011-12-05 2012-11-27 Method of dietary management of depression
US14/282,322 US20150024062A1 (en) 2011-12-05 2014-05-20 Medical Food for the Dietary Management of Major Depression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/686,372 Division US9220727B2 (en) 2011-12-05 2012-11-27 Method of dietary management of depression

Publications (1)

Publication Number Publication Date
US20150024062A1 true US20150024062A1 (en) 2015-01-22

Family

ID=47997755

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/686,372 Expired - Fee Related US9220727B2 (en) 2011-12-05 2012-11-27 Method of dietary management of depression
US14/282,322 Abandoned US20150024062A1 (en) 2011-12-05 2014-05-20 Medical Food for the Dietary Management of Major Depression
US14/534,290 Abandoned US20150064276A1 (en) 2011-12-05 2014-11-06 Method for the Dietary Management of Anxiety
US14/534,376 Abandoned US20150064277A1 (en) 2011-12-05 2014-11-06 Medical Food for the Dietary Management of Anxiety

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/686,372 Expired - Fee Related US9220727B2 (en) 2011-12-05 2012-11-27 Method of dietary management of depression

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/534,290 Abandoned US20150064276A1 (en) 2011-12-05 2014-11-06 Method for the Dietary Management of Anxiety
US14/534,376 Abandoned US20150064277A1 (en) 2011-12-05 2014-11-06 Medical Food for the Dietary Management of Anxiety

Country Status (9)

Country Link
US (4) US9220727B2 (en)
EP (1) EP2787842A2 (en)
JP (1) JP6134330B2 (en)
KR (1) KR101669741B1 (en)
CN (1) CN103987281B (en)
AU (1) AU2012348397B2 (en)
CA (1) CA2858192A1 (en)
RU (1) RU2482706C1 (en)
WO (1) WO2013085431A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954739B2 (en) 2018-11-19 2021-03-23 Saudi Arabian Oil Company Smart rotating control device apparatus and system

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482706C1 (en) * 2011-12-05 2013-05-27 Игорь Анатольевич Помыткин Therapeutic nutrition for dietary control of depression and anxious disorders and its application method
WO2014088441A1 (en) * 2012-12-03 2014-06-12 Igor Anatolievich Pomytkin Food for the dietary management of burnout
RU2542491C1 (en) * 2013-12-02 2015-02-20 Антон Сергеевич Чернопятко Using water low-deuterium water for increasing body resistance to aircraft flight
WO2015142209A1 (en) * 2014-03-20 2015-09-24 Igor Anatolievich Pomytkin Water with low deuterium content for the dietary management of psychological distress
JP2017526638A (en) * 2014-06-30 2017-09-14 ミトコンドリアル サブストレート インベンション リミテッドＭｉｔｏｃｈｏｎｄｒｉａｌ Ｓｕｂｓｔｒａｔｅ Ｉｎｖｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ Nutrient solutions for improving cognitive function
JP7406726B2 (en) 2020-06-24 2023-12-28 中国電力株式会社 Gas leak prevention device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292719A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method of Treating Metabolic Syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018545A1 (en) 1994-01-06 1995-07-13 Hyd Kutató-Fejlesztó Ktf. Food products for preventing development of diseases and process for preparing same
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US6872408B2 (en) * 2001-09-07 2005-03-29 Rupert C. Bell Method of treating bipolar disorders using deuterium-substituted carbonate
HU226984B1 (en) 2001-12-12 2010-04-28 Hyd Kutato Fejlesztoe Kft Medical and food products for treating diabetes mellitus and process for producing thereof
RU2270590C1 (en) * 2004-08-25 2006-02-27 Сергей Павлович Соловьев Drinking water with increased content of 1н2 16о and foodstuffs containing the same
EA012855B1 (en) * 2005-03-11 2009-12-30 Вада Консалтинг Лимитед Light pharmaceutical water, therapeutic compositions comprising thereof, methods for preparing thereof and use thereof
WO2007069933A1 (en) * 2005-12-12 2007-06-21 Vada Consulting Limited Method for decreasing postprandial glucose excursion
RU2338542C1 (en) * 2007-03-20 2008-11-20 Игорь Анатольевич Помыткин Application of water with lowered content of deuterium for preparation of agents of treatment of neurodegenerative diseases and improvement of cognitive function
RU2390491C2 (en) * 2007-05-08 2010-05-27 Вудфорд Ассошиэйтс Лимитэд Method and installation for production of light water
RU2482706C1 (en) * 2011-12-05 2013-05-27 Игорь Анатольевич Помыткин Therapeutic nutrition for dietary control of depression and anxious disorders and its application method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292719A1 (en) * 2005-12-12 2008-11-27 Igor Anatolievich Pomytkin Method of Treating Metabolic Syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954739B2 (en) 2018-11-19 2021-03-23 Saudi Arabian Oil Company Smart rotating control device apparatus and system

Also Published As

Publication number Publication date
RU2482706C1 (en) 2013-05-27
US20150064277A1 (en) 2015-03-05
EP2787842A2 (en) 2014-10-15
CN103987281B (en) 2016-05-04
US20130142883A1 (en) 2013-06-06
AU2012348397A1 (en) 2014-07-24
JP6134330B2 (en) 2017-05-24
WO2013085431A3 (en) 2013-08-01
AU2012348397B2 (en) 2016-07-28
JP2015500832A (en) 2015-01-08
KR101669741B1 (en) 2016-10-26
CA2858192A1 (en) 2013-06-13
CN103987281A (en) 2014-08-13
US20150064276A1 (en) 2015-03-05
KR20140103289A (en) 2014-08-26
US9220727B2 (en) 2015-12-29
WO2013085431A2 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US20150064277A1 (en) Medical Food for the Dietary Management of Anxiety
Molla et al. Risk factors for nutritional rickets among children in Kuwait
Hodgson et al. The metabolic and performance effects of caffeine compared to coffee during endurance exercise
Sullivan et al. Gastrostomy feeding in cerebral palsy: too much of a good thing?
Ahiropoulos Fluoride content of bottled waters available in Northern Greece
Fischer et al. Effect of a sodium and calcium DL‐β‐hydroxybutyrate salt in healthy adults
Gardner et al. Zinc supplementation: effects on the growth and morbidity of undernourished Jamaican children
Eichenberger et al. Effects of 3-week consumption of green tea extracts on whole-body metabolism during cycling exercise in endurance-trained men
Sawaya et al. Malnutrition, long-term health and the effect of nutritional recovery
Opydo-Szymaczek et al. Fluoride content of beverages intended for infants and young children in Poland
Paschall et al. Wine preference and related health determinants in a US national sample of young adults
Alghamdi et al. Mechanisms of obesity in children and adults with phenylketonuria on contemporary treatment
Emami The Impact of Pre-Cooling and CoQ10 Supplementation on Mediators of Inflammatory Cytokines in Elite Swimmers
Essed et al. No effect on intake and liking of soup enhanced with mono-sodium glutamate and celery powder among elderly people with olfactory and/or gustatory loss
Dasgupta Alcohol: pharmacokinetics, health benefits with moderate consumption and toxicity
Shibata et al. Calcium, magnesium, potassium and sodium intakes in Japanese children aged 3 to 5 years
RU2481009C1 (en) Dietary control of depression and anxious disorders, therapeutic nutrition and its application methods
Zeriouh et al. Effect of consumption of energy drinks and their toxicities.
Akpoghelie et al. Evaluation and consequences of the pH and caffeine content of energy drinks marketed in Delta State, Nigeria
Adhikari Estimation of Caffeine present in various soft drinks.
Khindria Evaluation of the effects of acute caffeine supplementation on selected cognitive domains in older women: a thesis presented in partial fulfillment of the requirements for the degree of Master of Science in Nutrition and Dietetics at Massey University, Albany, New Zealand
US20150313266A1 (en) Food for the dietary management of burnout
WO2015142209A1 (en) Water with low deuterium content for the dietary management of psychological distress
OZ et al. THE ORAL HEALTH-RELATED QUALITY OF LIFE IN PRESCHOOL CHILDREN FOLLOWING DENTAL TREATMENTS UNDER GENERAL ANESTHESIA
Fatima et al. Effect of consumption of energy drinks and their toxicities.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION